Wake-Promoting Pharmacotherapy for Psychiatric Disorders

  title={Wake-Promoting Pharmacotherapy for Psychiatric Disorders},
  author={Bernardo Dell’Osso and Cristina Dobrea and Laura Cremaschi and Chiara Arici and Alfredo Carlo Altamura},
  journal={Current Psychiatry Reports},
Medications promoting wakefulness are currently used in psychopharmacology in different contexts and with different objectives. In particular, they may be used for the treatment of syndromes that primarily show significant impairment in alertness/wakefulness (e.g., excessive sleepiness and other sleep disorders) as well as for the symptomatic treatment of different neuropsychiatric disorders that, in turn, are not exclusively characterized by sleep-wake disturbances (like mood disorders, for… 

Methylphenidate-induced psychosis in a young antipsychotic-naïve female patient

A case report of MPD-induced psychosis in a 31-year-old, antipsychotic-naïve patient is presented and careful evaluation is recommended each time MPD treatment is initiated.

Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects

Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities.

ADHD With Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical And Pharmacological Aspects Across The Lifespan.

A systematic review of the scientific literature on the neurobiological, clinical features and current pharmacological management of ADHD comorbid with BDs across the entire lifespan, with a major focus on the adulthood.

Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers

Sleep-wake states are impaired in various neurological disorders. Impairment of sleep-wake states can be an early condition that exacerbates these disorders. Therefore, treating sleep-wake

The Effects of the Atypical Dopamine Uptake Inhibitor CE-158 on Extracellular Dopamine in the Nucleus Accumbens

Through this study, it was determined that injections of CE-158 significantly increased extracellular DA levels in the nucleus accumbens, which has been linked to increases in effort-based decision making and other aspects of motivation in humans suffering from MDD.

Lifetime evolution of ADHD treatment

A naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan finds stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants are useful when a substance abuse history is detected.

Psikiyatrik Bozukluklarda Modafinil Kullanimiof Modafinil in Psychiatric Disorders

The aim of this article is to review the literature on clinical use of modafinil in psychiatric disorders and show initial promise for a variety of off-label indications in psychiatry, including bipolar disorder, attention-deficit/hyperactivity disorder, and schizophrenia.

Smart drugs and neuroenhancement: what do we know?

A systematic review of the association between smart drugs and neuro-enhancement found that the real prevalence is underestimated and it is important that the scientific community focus on this issue with further studies on animal models to validate their efficacy.

Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease

It is demonstrated that daily treatment with GSK189254 improved several behavioral measures in the Q175 mice including strengthening activity rhythms, cognitive performance and mood as measured by the tail suspension test and drugs targeting the H3R system may show benefits as cognitive enhancers in the management of HD.



Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression

Findings from reviewed studies suggested that pro-dopaminergic compounds, such as pramipexole and stimulants/stimulant-like agents, deserve consideration as adjunctive therapies in bipolar depressed patients, at least in some subgroups of patients.

Current and Emerging Options for the Drug Treatment of Narcolepsy

Night-time administration of a short-acting sedative, γ-hydroxybutyrate (sodium oxybate), has been used for the treatment for EDS and cataplexy and it is expected that more pathophysiology-based treatments will be available in the near future.

Approved and Investigational Uses of Modafinil

Modafinil had a substantial placebo effect on outcomes such as fatigue, excessive sleepiness and depression in patients with traumatic brain injury, major depressive disorder, schizophrenia, post-polio fatigue and multiple sclerosis; however, it did not provide any benefit greater than placebo.

Adjunctive stimulant use in patients with bipolar disorder: treatment of residual depression and sedation.

The present case series suggests that adjunctive stimulants may be a reasonable therapeutic option for treating residual depression and medication-induced sedation in some patients with bipolar disorder.

Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls

The progress associated with therapeutic attempts to restore orexin system function and treat neuropsychiatric conditions such as addiction, depression and anxiety are discussed.

Neurochemical Consequences of Dysphoric State During Amphetamine Withdrawal in Animal Models: A Review

This review focuses on the molecular aspects of AM PH withdrawal as indexed by neurochemical parameters under a variety of injection regimens in rodent models which exhibit significant phenotypic features relevant to the syndromes of AMPH withdrawal in humans.

Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder

The cardiovascular safety of drugs such as methylphenidate, amphetamines and atomoxetine is examined with regard to effects on blood pressure, heart rate, ECG parameters and the risk of sudden death.

An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy.

In patients with MDD who experience sedation as a side effect of antidepressant therapy, adjunctive modafinil improved wakefulness and reduced fatigue and modafInil plus SSRIs also improved mood and quality of life.

Effect of Modafinil on Impairments in Neurobehavioral Performance and Learning Associated with Extended Wakefulness and Circadian Misalignment

Modafinil reduced the neurobehavioral impairment associated with work, both during prolonged wakefulness and at adverse circadian phases, without adversely affecting subjective alertness or subsequent sleep, which suggest that modafInil might be a particularly relevant countermeasure against the deleterious effects of prolonged work hours, shift work, and transmeridian travel.